Based on the results of these primary analyses, our secondary aims were to test whether plasma concentrations of GFAP and other blood biomarkers differed by APOE ε4 status and to test associations between brain and plasma concentrations of GFAP in the 5XFAD transgenic mouse model of AD. Here, GFAP is linked to Alzheimer disease.